Evidence map›Paper›PMID 39885205›Full record

ArticleScientific reports2025

TOP2A inhibition and its cellular effects related to cell cycle checkpoint adaptation pathway.

Maria Arroyo, M A Fernández-Mimbrera, E Gollini, A Esteve-Codina, A Sánchez, Juan Alberto Marchal

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Maria Arroyo *Cell Biology and Epigenetics, Department of Biology, Technical University of Darmstadt, Darmstadt, Germany. arroyo.lopez.mc@gmail.com.
M A Fernández-Mimbrera *Departamento Biología Experimental, Universidad de Jaén, Paraje Las Lagunillas S/N E23071, Jaén, Spain.
E GolliniDepartamento Biología Experimental, Universidad de Jaén, Paraje Las Lagunillas S/N E23071, Jaén, Spain.
A Esteve-CodinaCentre Nacional d'Anàlisi Genòmica (CNAG), Baldiri Reixac 4, 08028, Barcelona, Spain.
A SánchezDepartamento Biología Experimental, Universidad de Jaén, Paraje Las Lagunillas S/N E23071, Jaén, Spain.
Juan Alberto MarchalDepartamento Biología Experimental, Universidad de Jaén, Paraje Las Lagunillas S/N E23071, Jaén, Spain. jamaor@ujaen.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigate the G2 checkpoint activated by chromosome entanglements, the so-called Decatenation Checkpoint (DC), which can be activated by TOP2A catalytic inhibition. Specifically, we focus on the spontaneous ability of cells to bypass or override this checkpoint, referred to as checkpoint adaptation. Some factors involved in adapting to this checkpoint are p53 and MCPH1. Using cellular models depleted of p53 or both p53 and MCPH1 in hTERT-RPE1 cells, we analyzed cell cycle dynamics and adaptation, segregation defects, apoptosis rate, and transcriptional changes related to prolonged exposure to TOP2A inhibitors. Our findings reveal that cell cycle dynamics are altered in MCPH1-depleted cells compared to control cells. We found that MCPH1 depletion can restore the robustness of the DC in a p53-negative background. Furthermore, this research highlights the differential effects of TOP2A poisons and catalytic inhibitors on cellular outcomes and transcriptional profiles. By examining the different mechanisms of TOP2A inhibition and their impact on cellular processes, this study contributes to a deeper understanding of the regulation and physiological implications of the DC and checkpoint adaptation in non-carcinogenic cell lines.

Indexed as

Cell Cycle CheckpointsDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTopoisomerase II InhibitorsApoptosisCell LineHumansTumor Suppressor Protein p53DNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTOP2A protein, humanTopoisomerase II InhibitorsTP53 protein, humanTumor Suppressor Protein p53Checkpoint adaptationG2 checkpointICRF193MCPH1MicroscopyTOP2A inhibition

Identifiers

PMID39885205
PMCPMC11782647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.